<DOC>
	<DOCNO>NCT01279538</DOCNO>
	<brief_summary>The purpose study ass Pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , safety tolerability ASKP1240 administer subject receive de novo kidney transplant .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetic , Pharmacodynamic , Safety Tolerability ASKP1240 de Novo Kidney Transplantation</brief_title>
	<detailed_description />
	<criteria>Subject recipient de novo kidney transplant living decease donor Prior randomization , subject posttransplant serum creatinine value least 30 % decrease pretransplant value require dialysis Female subject child bear potential must negative serum pregnancy test within 7 day prior enrollment upon hospitalization must agree maintain effective birth control study All sexually active male subject must agree use adequate method contraception throughout study period 90 day last dose study drug agree sperm donation end study , 90 day last dose study drug , whichever longer Subject must willing able comply study requirement include prohibited concomitant medication restriction Prior randomization , subject receive antibody induction therapy ( e.g. , thymoglobulin , basiliximab , daclizumab , OKT3 , alemtuzumab ) Subject previously receive receive organ transplant kidney Recipient positive T B cell crossmatch Subject ABO blood type incompatibility donor Subject receive intravenous immunoglobulin ( IVIG ) therapy 3 month prior first dose study drug Recipient donor know medical history seropositive human immunodeficiency virus ( HIV ) Subject thromboembolic event ( e.g. , myocardial infarction , cerebrovascular event , pulmonary embolus , deep vein thrombosis , peripheral arterial thromboembolic event ) past 5 year subject specific therapy prophylaxis treatment event . Low dose aspirin ( 81 mg ) therapy consider exclusionary . NOTE : A onetime event arteriovenous ( AV ) fistula dialysis access thrombosis exclusionary . Subjects recurrent AV fistula thrombosis systemic medication prevent reoccurrence exclude Subject current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully Subject uncontrolled concomitant infection unstable medical condition could interfere study objective Subject concurrently participate another drug study receive investigational drug 8 week ( depend medication ) prior transplant Subject previously receive ASKP1240 participate study involve ASKP1240 Subject abnormal chest xray indicative acute chronic lung disease prior examination within 3 month prior randomization Subject abnormal electrocardiogram ( ECG ) consider clinically significant prior examination within 3 month prior randomization Subject uncontrolled intercurrent illness , include , limited ongoing active infection , clinically significant cardiac disease , seizure disorder , psychiatric illness/social situation would limit compliance study requirement Subject receive live live attenuate virus vaccination within last 30 day prior first dose study drug Subject clinical condition would allow safe conduct completion study Subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>ASKP1240</keyword>
</DOC>